ZanoliMuMab
Modify Date: 2025-08-25 18:40:30
ZanoliMuMab structure
|
Common Name | ZanoliMuMab | ||
|---|---|---|---|---|
| CAS Number | 652153-01-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZanoliMuMabZanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma[1]. |
| Name | ZanoliMuMab |
|---|
| Description | Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Zanolimumab (10 and 100 ng/mL) shows strong killing of the CD4+ T cells with a better effect to CD45RO+ subset than the CD45RA+ subset[1]. Zanolimumab (1-10000 ng/mL) Fc and dose-dependently down-regulates the level of CD4 from purified primary CD4+ T cells and SUP-T1 T cells[1]. Zanolimumab (1-10000 ng/mL) potently inhibits of TCR-stimulated T-cell proliferation both in tetanus toxin induced and anti-CD3 induced T-cell proliferation[1]. Zanolimumab (0-30 min) inhibits TCR signal transduction[1]. |
| References |
| No Any Chemical & Physical Properties |